An observational study in Sarcopenic Obesity, Obesity and Sarcopenia, sponsored by The Swedish School of Sport and Health Sciences. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by The Swedish School of Sport and Health Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies in Obesity with a site in Sweden — 38 open to participants now, 49 under way, 8 of them phase 3. Obesity · Sweden.
Among the 179 studies in Obesity with a site in Sweden, this one is the 20th largest by planned enrollment of the 30 observational ones that give a count, is one of 6 that started in 2020, is one of 30 observational ones, reaches primary completion later than 11 of the 48 other live ones, and was the 147th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →38 of the 179 studies in Obesity with a site in Sweden are open now. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden
Ages 18–64 · Women only
AstraZeneca · Sites in Sweden, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Sweden, United States, Belgium and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Sweden, United States, Greece and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in Sweden, Germany
Ages 18–70 · Healthy volunteers
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 18 · Phase 3 27 · Phase 4 7
First in 1987; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 110 across the 149 interventional studies, 103 across the 30 observational. Of the 109 that completed or were terminated, 12 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 179 have an industry lead sponsor. The 10 most frequent:
The Swedish School of Sport and Health Sciences is the lead sponsor of 12 studies on the registry; 5 are open to participants now.
The Swedish School of Sport and Health Sciences has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07213245Göteborg UniversityMetabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF) | 2026-12-31 |
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
| NCT07665879Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 179 studies in Obesity with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The coexistence of obesity and sarcopenia results in sarcopenic obesity, a high-risk geriatric condition associated with metabolic perturbations and several co-morbidities. Despite the rising numbers of older adults diagnosed with sarcopenic obesity, few studies have characterized this condition on the muscle cell and systemic level. This study sought to comprehensively assess the influence of sarcopenic obesity on muscle and blood-related parameters and compare it to non-sarocopenic obese and non-sarcopenic lean older adults.
The elderly participants will be community-dwelling living in the greater Stockholm metropolitan area. Participants will be recruited through local senior clubs, online communities, advertisement and word of mouth.
The young participants will be living in the greater Stockholm metropolitan area. Participants will be recruited through university forums, online communities, advertisement and word of mouth.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Age: 70-80 years Men, ALM/W \< 25.7 %, body fat % \> 35 Women, ALM/W \< 19.7 %, body fat % \> 40
Dietary Supplement: Essential amino acids (EAA)
Age: 70-80 years Men, ALM/W \> 25.7 %, body fat % \> 35 Women, ALM/W \> 19.7 %, body fat % \> 40
Dietary Supplement: Essential amino acids (EAA)
Age: 70-80 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32
Dietary Supplement: Essential amino acids (EAA)
Age: 18-40 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32
Dietary Supplement: Essential amino acids (EAA)
intake of 240 mg EAA per kg lean body mass after a resistance exercise session
Fiber type-specific cell signalling
This measure will be investigated during an experimental trial in which the participants are subjected to an acute bout of resistance exercise followed by the ingestion of essential amino acids (240 mg/kg lean mass). During this 3 hour time period, the participants will donate two muscle biopsies, one before exercise and the second one 1 hour after exercise. Cell signalling networks related to muscle mass regulation will be examined in these biopsy samples. The signal will be measured using Western blotting and the signal obtained is expressed in relation to baseline (adjusted volume intensity).
Time frame: 1 hour after ingestion of essential amino acids and resistance exercise
Skeletal muscle fiber characteristics
Fiber type-specific area measured using immunofluorescence microscope in muscle biopsies collected at baseline (prior to ingestion of essential amino acids and resistance exercise). Unit of measurement is square micrometers (µm\^2).
Time frame: 1 hour prior to ingestion of essential amino acids and resistance exercise
Whole body muscle volume
Indices of muscle volume and fat infiltration obtained with magnetic resonance imaging (MRI). Unit of measurement is cubic centrimeters (cm\^3).
Time frame: 1 hour
Whole body glucose tolerance
Oral glucose tolerance test in which the participants will ingest a standardized glucose drink and blood glucose levels will be monitored throughout a period of 2 hours. Unit of measurement is mmol/L glucose.
Time frame: 2 hours
Accelerometer-assessed physical activity levels
Hip-worn accelerometer data (Actigraph GT3X) collected over 7 consecutive days. Unit of measurement is steps per day.
Time frame: 1 week
Isometric and isokinetic leg muscle strength
Muscle performance will be evaluated at a single timepoint during the study using IsoMed2000 dynamometer. Participants will perform a maximal isometric contraction at 60 degrees of knee flexion. Unit of measurement is Newton meter (N-m).
Time frame: 1 hour
PDFs hosted by the registry, ClinicalTrials.gov.
Started Jan 2020 (actual). Primary completion is estimated for Dec 2025, 70 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Swedish School of Sport and Health Sciences